NLPDP Biosimilars Initiative

Announced in March 2023, under the Biosimilars Initiative, NLPDP beneficiaries using Copaxone, Enbrel, Humalog, Humira, Lantus, Lovenox, NovoRapid, Remicade and Rituxan, are required to transition to a safe and effective biosimilar version no later than March 31, 2024, in order to maintain drug plan coverage. With under a month remaining in the transition period, about 35% of patients using Lantus, NovoRapid or Humalog, have yet to be transitioned to a biosimilar insulin.

The NLPDP Biosimilars webpage contains useful resources for physicians and other health professionals to support patients through this transition period.

NLPDP Biosimiliars Biosimilars Initiative – Physician letter Insulin- FINAL Mar 2023 on letterhead Download